A graft-versus-myeloma effect has been previously induced by infusing high numbers of donor lymphocytes after allogeneic stem cell transplantation in relapsed/refractory multiple myeloma (MM) patients. A 43-year-old patient with MM refractory to standard chemotherapy and autologous transplantation received an allogeneic HLA-matched T cell-depleted marrow transplant from his sister after conditioning with single dose total-body irradiation, melphalan and cyclophosphamide. Twenty-four months after transplant neither a significant reduction of serum M protein nor evidence of acute or chronic graft-versus-host disease (GVHD) were observed. The patient was then treated with four escalating low doses of donor lymphocyte infusions (DLI) (0.1, 1.0, 5.0 and 5.0 × 10 6 CD3 + T cells/kg, respectively) over a 13 month period. Following the second infusion a mild liver acute GVHD and a partial, but transient, response occurred. After the last DLI the patient achieved a complete remission and developed extensive chronic GVHD. However, concomitant with the disappearance of clonal plasma cells from the marrow and of serum M protein, two new bone lytic lesions appeared requiring treatment with radiotherapy. In conclusion, escalating low doses of DLI may be effective in MM and may prevent severe acute but not chronic GVHD. However, the efficacy of DLI in extramedullary MM lesions is still unclear. Keywords: MM; BMT; GVM; DLI Allogeneic bone marrow transplantation may cure many hematologic malignancies, but is often complicated by severe, and even lethal adverse immunological effects such as acute graft-versus-host disease (GVHD). In particular, initial studies of allogeneic stem cell transplant in multiple myeloma showed high morbidity and mortality, 1 although molecular disappearance of the disease was also obtained in a limited number of cases.
Allogeneic bone marrow transplantation may cure many hematologic malignancies, but is often complicated by severe, and even lethal adverse immunological effects such as acute graft-versus-host disease (GVHD). In particular, initial studies of allogeneic stem cell transplant in multiple myeloma showed high morbidity and mortality, 1 although molecular disappearance of the disease was also obtained in a limited number of cases. 2 However, better selection of patients as well as the use of different conditioning regimens are likely to contribute to reduced transplant-related mortality in more recent reports. 3 Nonetheless, because of frequent relapses after allotransplant, induction of a graftversus-myeloma effect may be attempted by donor lymphocyte infusion (DLI). DLI, in fact, has been demonstrated to represent the most effective salvage therapy for chronic myeloid leukemia (CML) patients relapsed in chronic phase after allogeneic BMT, 4 and it is conceivable that an antitumor alloimmune effect may also be obtained in other hematologic and non-hematologic disorders. At this time more data are needed to establish the role and the doses of DLI in multiple myeloma, which has been successful in a recent series of patients receiving high numbers of donor lymphocytes.
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Case report
A 43-year-old man (UPN 207) underwent an allogeneic BMT in September 1994. He had been diagnosed with IgG/k multiple myeloma, stage IIIA in October 1993 and after seven cycles of the CMVP chemotherapy regimen (including vincistine, cyclophosphamide, BCNU, melphalan, doxorubicin and prednisone), radiotherapy on T6-T7 and intermediate-dose intensive chemotherapy with autologous rescue the disease was unresponsive. Pre-transplant monoclonal IgG was 3.116 g/dl, there were 12 lytic bone lesions and the plasma cell infiltration of bone marrow was 40%. He received marrow from his fully HLA-identical sister after preparation with 10 Gy single dose TBI, 120 mg/kg cyclophosphamide, and 100 mg/m 2 melphalan. GVHD prophylaxis consisted of T cell depletion with the Campath 1-G monoclonal antibody. The number of T lymphocytes infused was 0.5 × 10 6 /kg. The post-transplant course was totally uneventful with complete engraftment achieved on day 33 and without any sign of acute or chronic graft-versus-host disease (GVHD). However, the serum M protein evaluated 6, 12 and 24 months after transplantation was stable over 2.0 g/dl, the plasma cell bone marrow infiltration was 10% and no further bone lytic lesions were documented by radiological investigation. Chimerism analysis evaluated by karyotypic examination of marrow cells 24 months after transplant showed 50% donor female cells. The patient was then treated with escalating doses of DLI starting from 10 5 CD3 + T cells/kg 25 months after BMT, which neither induced aGVHD nor affected the serum M protein, followed 1 month later by 10 6 CD3 + T cells/kg which induced a mild liver aGVHD not requiring immunosuppressive therapy and resulted in a Ͼ50% rapid decrease of the M component. At this time full donor chimerism in the marrow and a four-fold increase of circulating CD8 + T cells with NK phenotype (CD57 + ) were detected. The post-DLI course is shown in Figure 1 . Nine months later, when a significant new increase of serum M protein occurred, 5 × 10 6 CD3 + T cells/kg were infused obtaining again a slight reduction of the serum protein. Three months later the same T cell dose was infused but at the same time a new bone lytic lesion appeared. Two months later, while the M component was progressively disappearing another bone lesion was documented.
Concomitantly, signs of chronic GVHD involving the eyes, the mouth and the liver were observed and progressed to extensive scleroderma-like skin involvement, heart and pleural effusion requiring hospitalization and multiple treatment. Now, 12 months after the last DLI, the lytic lesions have been treated with radiotherapy, no monoclonal plasma cells are present in bone marrow biopsy and serum M component is undetectable by immunofixation analysis. The patient has a Karnofsky score of 70% and is receiving azathioprine and steroid treatment for cGVHD.
Discussion
The role of an anti-tumor immune effect by DLI in disorders other than CML is still a matter for discussion considering the high risk of severe complications such as GVHD or marrow aplasia reported in different series of transplanted patients affected by hematological neoplasia including MM. In fact, in this latter disease it has not yet been shown what might be the best dose of allogeneic lymphocytes to be infused in order to obtain a graft-versusmyeloma effect with no or limited GVHD. [6] [7] [8] It has recently been reported 5 that eight out of 13 MM patients obtained a clinical response after DLI, where four patients who received doses Ͼ1 × 10 8 T cells/kg and four doses р1 × 10 8 T cells/kg achieved a complete or a partial remission. In six cases, there was acute GVHD grade II-III, with two deaths due to concomitant marrow aplasia, and six patients developed chronic GVHD. The clinical efficacy of DLI was mostly associated with concomitant acute and/or chronic GVHD although the majority of responding patients were shown to be 'fully donor' by analysis of chimerism before DLI.
In the case that we report here escalating doses of DLI allowed us to obtain the complete disappearance of the serum M component by infusing four doses of donor T cells р0.5 × 10 7 /kg, with a total of 1.11 × 10 7 T cells/kg infused over a 13-month period.
Since the potential immunogenicity of malignant mature B cells is likely to be due to minor histocompatibility antigens of the host and to the presence of the idiotype as a tumor-specific, and even a patient-specific antigen potentially triggering T cells, 9 it is conceivable that these latter cells are important anti-MM effectors. Therefore, the small immune effect against MM cells after T cell-depleted allogeneic transplant could be overcome by several small doses of DLI. The appearance of a progressive cGVHD and GVM suggests that escalating doses of DLI may be very effective in MM and may prevent severe acute GVHD, but they do not prevent extensive cGVHD development.
Another issue concerns the development of new bone lytic lesions while observing a dramatic reduction of the serum M component. Although a biopsy of new lesions was not performed, it is conceivable that they might be related to a progression of the disease since they were successfully treated with radiotherapy and neither the occurrence of a systemic relapse nor signs of another cancer have been observed 1 year after treatment. Therefore, it can be hypothesized that circulating allo-T cells may not reach or may not bind to plasma cells in the bone efficiently, or that bone microenviroment may secrete cytokines, such as TGF-␤, suppressing T cell function. 10 Finally, it is not known whether small doses of DLI allow a sufficiently high frequency of cytotoxic T cells to exert an anti-tumor effect in extramedullary lesions.
